LONDON/STOCKHOLM (Reuters) – Sweden’s Investor AB and Priveq Investment are exploring a sale or flotation of Swedish Orphan, their jointly owned maker of drugs for rare diseases, two people familiar with the matter said on Friday.
Morgan Stanley and SEB Enskilda, part of Swedish banking group SEB (SEBa.ST), are likely to act as advisers on what could be a 350 million euros ($469 million)-plus sale, one of the people said.
Swedish Orphan Chief Executive Bo Jesper Hansen told Reuters: “We are looking into, or evaluating, the different strategic options that we might pursue.”
“Part of that is to find well-reputed banks to give us advice, and we have some meetings going on with different banks but nothing is decided yet,” he added.
Investor AB (INVEb.ST) declined to comment. Priveq was not immediately available for comment.
By Quentin Webb and Sven Nordenstam
(Additional reporting by Niklas Pollard in Stockholm; Editing by Douwe Miedema)
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.